KOL KNOCKOUTTM: Retina Edition | Challenging Cases & Expert -

Name: KOL KNOCKOUT™: Retina Edition | Challenging Cases & Expert Opinions - Round 1
Uploaded: 2023-10-02T04:00:00+00:00
Duration: 1 h 2 min 24 s
Description: This popular CME program is a fun and exciting game show-style quiz competition that features key opinion leaders (KOLs) as contestants. Hosted by Progra

Media formats available:

Details

Presenters

Overview
This popular CME program is a fun and exciting game show-style quiz competition that features key opinion leaders (KOLs) as contestants.
Hosted by Program Chair Sunil K. Srivastava, MD, the first of three rounds featured Parisa Emami Naeini, MD, MPH; Prethy Rao, MD, MPH; and Yoshihiro Yonekawa, MD. The KOLs weighed in on their preferred treatment approach to various challenging case studies presented by Dr. Srivastava. Tune in to find out who won!
This content was captured during a live symposium. Voting took place during the symposium.

This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Appraise medical and surgical management approaches for common retinal diseases and their sequelae
- Diagnose vitreoretinal pathology by performing thorough clinical exams and using advanced imaging modalities
- Discuss how fluidics, intraocular tamponades, cutting rates, and gauge of surgery can impact surgical outcomes
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Sunil K. Srivastava, MD
Surgical Retina Fellowship Director
Cleveland Clinic
Cole Eye Institute
Cleveland, OH

Parisa Emami-Naeini, MD, MPH
Assistant Professor of Ophthalmology
University of California Davis
Davis, CA

Prethy Rao, MD, MPH
Retina and Vitreous of Texas
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX

Yoshihiro Yonekawa, MD
Associate Professor of Ophthalmology
Wills Eye Hospital, Mid Atlantic Retina
Thomas Jefferson University
Philadelphia, PA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Sunil K. Srivastava, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Bausch + Lomb, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevensys, and Novartis. Grant/Research Support: Bausch + Lomb, EyePoint Pharmaceuticals, Eyevensys, and Regeneron.
Parisa Emami-Naeini, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Bausch + Lomb, EyePoint Pharmaceuticals, and Genentech.
Prethy Rao, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Bausch + Lomb, DORC, EyePoint Pharmaceuticals, Iveric Bio, and Vortex. Grant/Research Support: Regenxbio. Speaker's Bureau: Regeneron.
Yoshihiro Yonekawa, MD,has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch Health, EyePoint Pharmaceuticals, Regeneron, and Versant Health. Grant/Research Support: Genentech, Janssen, Kodiak, and Regeneron.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 10/02/2023
Expiration Date: 10/02/2024